Becton, Dickinson and Company (NYSE:BDX) Declares Quarterly Dividend of $1.05

Key Points

• Becton, Dickinson declared a quarterly dividend of $1.05 per share, with shareholders of record on June 9 and payment on June 30, implying a yield of about 2.9% (ex-dividend date June 9).
• The company has raised its dividend for 53 consecutive years and maintains a conservative payout ratio (around 28.5%), with analysts and company guidance indicating earnings coverage should remain strong.
• In the latest quarter BDx reported $2.91 EPS (beat) but revenue missed at $4.49B, and management set FY2026 EPS guidance of $12.35–$12.65 (analyst consensus roughly $12.56); the board also authorized a $10 million share repurchase plan.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) declared a quarterly dividend on Tuesday, April 28th. Shareholders of record on Tuesday, June 9th will be paid a dividend of 1.05 per share by the medical instruments supplier on Tuesday, June 30th. This represents a c) annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th.

Becton, Dickinson and Company has raised its dividend by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 53 consecutive years. Becton, Dickinson and Company has a dividend payout ratio of 28.5% indicating that its dividend is sufficiently covered by earnings. Analysts expect Becton, Dickinson and Company to earn $13.73 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 30.6%.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $146.75 on Wednesday. The company has a market cap of $41.79 billion, a price-to-earnings ratio of 23.95, a PEG ratio of 10.68 and a beta of 0.29. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The stock has a fifty day moving average price of $162.11 and a 200-day moving average price of $182.48.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts' consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business had revenue of $4.49 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the previous year, the firm earned $3.43 earnings per share. Becton, Dickinson and Company's revenue for the quarter was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.56 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has approved a stock repurchase plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.